CAR T Cells

Thilan Tudor; Zev A Binder; Donald M O'Rourke

doi:10.1016/j.nec.2020.12.005

CAR T Cells

Neurosurg Clin N Am. 2021 Apr;32(2):249-263. doi: 10.1016/j.nec.2020.12.005. Epub 2021 Feb 18.

Authors

Thilan Tudor¹, Zev A Binder², Donald M O'Rourke³

Affiliations

¹ University of Pennsylvania, 3600 Hamilton Walk, Stemmler Hall, Room 176, Philadelphia, PA 19104.
² University of Pennsylvania, 3600 Hamilton Walk, Stemmler Hall, Room 176, Philadelphia, PA 19104. Electronic address: Zev.Binder@pennmedicine.upenn.edu.
³ John Templeton, Jr. M.D. Professor in Neurosurgery, Hospital of the University of Pennsylvania, 3400 Spruce St. Philadelphia, PA 19104, USA. Electronic address: https://twitter.com/DrORourke2.

PMID: 33781506
DOI: 10.1016/j.nec.2020.12.005

Abstract

Chimeric antigen receptor T (CAR-T) cells, an immunotherapy that demonstrates marked success in treatment of hematologic malignancies, are an emergent therapeutic for patients with glioblastoma (GBM). GBM CAR-T trials have focused on targeting well-characterized antigens in the pathogenesis of GBM. Early stage trials demonstrate initial success in terms of safety and tolerability. There is preliminary evidence of antitumor activity and localization of the CAR-T product to tumoral sites. There are mixed results regarding patient outcomes. Ongoing GBM CAR-T trials will target novel antigens, explore CAR-T combination therapy, design multivalent CAR constructs, and assess the impact of lymphodepletion before CAR-T delivery.

Keywords: CAR-T; Chimeric antigen receptor; Chimeric antigen receptor T cell; Glioblastoma; Immunotherapy; Trial.

Publication types

Review

MeSH terms

Glioblastoma* / therapy
Humans
Immunotherapy, Adoptive
Receptors, Chimeric Antigen*
T-Lymphocytes

Substances

Receptors, Chimeric Antigen